BACKGROUND: The presence of microvascular obstruction (MVO) after primary ST-segment elevation acute myocardial infarction (STEMI) is associated with a poor outcome. The aim of the paper was to examine the relationship between distinct monocyte subsets and gadolinium-enhanced cardiovascular magnetic resonance (CMR) characteristics of MVO after STEMI. METHODS AND RESULTS: Seventy-one patients with primary STEMI successfully treated with stenting were enrolled in the study. Two monocyte subsets (CD14(+)CD16(-) and CD14(+)CD16(+)) were measured on flow cytometry on admission and 2, 3, 4, 5, 8 days after the onset of STEMI. CMR was performed 7 days after revascularization to determine MVO on late gadolinium-enhanced imaging. The peak levels of CD14(+)CD16(-) monocytes, but not those of CD14(+)CD16(+) monocytes, were significantly higher in patients with MVO than in those without MVO. A multivariate logistic regression model showed that the post-perfusion peak levels of CD14(+)CD16(-) monocytes remained an independent factor for the presence of MVO (odds ratio=1.53; 95% confidence interval: 1.01-2.32; P=0.04). The absence of MVO was significantly associated with improvement in left ventricular ejection fraction. CONCLUSIONS: Post-reperfusion enhancement of CD14(+)CD16(-) monocytes was associated with MVO in patients with STEMI. The pathophysiologic and therapeutic implications of this association require further study.
BACKGROUND: The presence of microvascular obstruction (MVO) after primary ST-segment elevation acute myocardial infarction (STEMI) is associated with a poor outcome. The aim of the paper was to examine the relationship between distinct monocyte subsets and gadolinium-enhanced cardiovascular magnetic resonance (CMR) characteristics of MVO after STEMI. METHODS AND RESULTS: Seventy-one patients with primary STEMI successfully treated with stenting were enrolled in the study. Two monocyte subsets (CD14(+)CD16(-) and CD14(+)CD16(+)) were measured on flow cytometry on admission and 2, 3, 4, 5, 8 days after the onset of STEMI. CMR was performed 7 days after revascularization to determine MVO on late gadolinium-enhanced imaging. The peak levels of CD14(+)CD16(-) monocytes, but not those of CD14(+)CD16(+) monocytes, were significantly higher in patients with MVO than in those without MVO. A multivariate logistic regression model showed that the post-perfusion peak levels of CD14(+)CD16(-) monocytes remained an independent factor for the presence of MVO (odds ratio=1.53; 95% confidence interval: 1.01-2.32; P=0.04). The absence of MVO was significantly associated with improvement in left ventricular ejection fraction. CONCLUSIONS: Post-reperfusion enhancement of CD14(+)CD16(-) monocytes was associated with MVO in patients with STEMI. The pathophysiologic and therapeutic implications of this association require further study.
Authors: Han Wu; Ran Li; Kun Wang; Dan Mu; Jian-Zhou Chen; Xuan Wei; Xue Bao; Zhong-Hai Wei; Jun Xie; Biao Xu Journal: Cardiol Res Pract Date: 2020-09-26 Impact factor: 1.866
Authors: Frauke S Czepluch; Magdalena Schlegel; Felix Bremmer; Carl L Behnes; Gerd Hasenfuss; Katrin Schäfer Journal: Virchows Arch Date: 2013-07-20 Impact factor: 4.064